LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Harvard Bioscience Inc

Geschlossen

BrancheGesundheitswesen

0.66 3.13

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.63

Max

0.73

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.1M

-1.2M

Verkäufe

141K

21M

Gewinnspanne

-5.978

Angestellte

330

EBITDA

42K

197K

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+203.03% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

321K

26M

Vorheriger Eröffnungskurs

-2.47

Vorheriger Schlusskurs

0.66

Nachrichtenstimmung

By Acuity

50%

50%

185 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Harvard Bioscience Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Nov. 2025, 18:59 UTC

Wichtige Markttreiber

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17. Nov. 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17. Nov. 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17. Nov. 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17. Nov. 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17. Nov. 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17. Nov. 2025, 22:02 UTC

Ergebnisse

Trip.com Group 3Q Rev $2.6B >TCOM

17. Nov. 2025, 22:02 UTC

Ergebnisse

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17. Nov. 2025, 22:02 UTC

Ergebnisse

Trip.com Group 3Q EPS $4.02 >TCOM

17. Nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Nov. 2025, 21:40 UTC

Ergebnisse

James Hardie Industries 2Q Adj EPS 26c >JHX

17. Nov. 2025, 21:40 UTC

Ergebnisse

James Hardie Industries 2Q Loss/Shr 10c >JHX

17. Nov. 2025, 21:39 UTC

Ergebnisse

James Hardie Industries 2Q Sales $1.29B >JHX

17. Nov. 2025, 21:38 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. Nov. 2025, 21:38 UTC

Ergebnisse

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17. Nov. 2025, 21:10 UTC

Ergebnisse

XP Inc. 3Q EPS BRL2.47 >XP

17. Nov. 2025, 21:10 UTC

Ergebnisse

XP Inc. 3Q Rev BRL4.67B >XP

17. Nov. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17. Nov. 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17. Nov. 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Nov. 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17. Nov. 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17. Nov. 2025, 19:16 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. Nov. 2025, 18:20 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17. Nov. 2025, 16:45 UTC

Akquisitionen, Fusionen, Übernahmen

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17. Nov. 2025, 16:16 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. Nov. 2025, 16:15 UTC

Ergebnisse

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17. Nov. 2025, 15:40 UTC

Akquisitionen, Fusionen, Übernahmen

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17. Nov. 2025, 15:22 UTC

Akquisitionen, Fusionen, Übernahmen

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17. Nov. 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer-Vergleich

Kursveränderung

Harvard Bioscience Inc Prognose

Kursziel

By TipRanks

203.03% Vorteil

12-Monats-Prognose

Durchschnitt 2 USD  203.03%

Hoch 2 USD

Tief 2 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harvard Bioscience Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

0.3 / 0.3401Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

No Evidence

Langfristig

No Evidence

Stimmung

By Acuity

185 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat